(PRESS RELEASE) PARIS, 28-Apr-2022 — /EuropaWire/ — ATTD 2022 – Diabeloop, pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany. The data show a constant improvement in Time In Range (70-180 … Read the full press release →
Posted in Artificial Intelligence (AI), Denmark, France, Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged Accu-Chek Insight, AI, aid, artificial-intelligence, ATTD 2022, automated insulin delivery, biphasic boluses, blood sugar level, DBL-hu, DBLG1, DBLG1 iController, DBLG1 System, Diabeloop, Diabetes, diabetes management, Erik Huneker, glucose control, glycemic control, HbA1c, Insulin Pump, postprandial hyperglycemia, Prof. Pierre-Yves Benhamou, real-life DBLG1 cohort, reduction of hypoglycemia, reduction of hypoglycemic episodes, Roche, Stéphanie JEGU, T1D, Time In Range, TIR, type 1 diabetes, WP7, WP72 study, YourLoops